TY - JOUR
T1 - The Masking Game
T2 - Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control
AU - Lucchi, Roberta
AU - Bentanachs, Jordi
AU - Oller-Salvia, Benjamí
N1 - Funding Information:
B.O.-S. acknowledges funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 844441. R.L. is grateful to IQS for a Ph.D. fellowship (2019−2020) and to the Spanish Ministry of Science, Innovation and Universities for an FPU fellowship (FPU19/03216). We acknowledge support from the Agència de Gestió d’Ajuts Universitaris i de Recerca (Generalitat de Catalunya) under the grant agreement SGR 2017 1559. All the figures in this article have been created with BioRender.
Publisher Copyright:
© 2021 The Authors. Published by American Chemical Society.
PY - 2021/5/26
Y1 - 2021/5/26
N2 - The high selectivity and affinity of antibody binding have made antibodies all-pervasive tools in therapy, diagnosis, and basic science. A plethora of chemogenetic approaches has been devised to make antibodies responsive to stimuli ranging from light to enzymatic activity, temperature, pH, ions, and effector molecules. Within a single decade, the field of activatable antibodies has yielded marketed therapeutics capable of engaging antigens that could not be targeted with traditional antibodies, as well as new tools to control intracellular protein location and investigate biological processes. Many opportunities remain untapped, waiting for more efficient and generally applicable masking strategies to be developed at the interface between chemistry and biotechnology.
AB - The high selectivity and affinity of antibody binding have made antibodies all-pervasive tools in therapy, diagnosis, and basic science. A plethora of chemogenetic approaches has been devised to make antibodies responsive to stimuli ranging from light to enzymatic activity, temperature, pH, ions, and effector molecules. Within a single decade, the field of activatable antibodies has yielded marketed therapeutics capable of engaging antigens that could not be targeted with traditional antibodies, as well as new tools to control intracellular protein location and investigate biological processes. Many opportunities remain untapped, waiting for more efficient and generally applicable masking strategies to be developed at the interface between chemistry and biotechnology.
UR - http://www.scopus.com/inward/record.url?scp=85106643002&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000657243600007&DestLinkType=FullRecord&DestApp=WOS_CPL
UR - http://hdl.handle.net/20.500.14342/3723
U2 - 10.1021/acscentsci.0c01448
DO - 10.1021/acscentsci.0c01448
M3 - Article
C2 - 34079893
AN - SCOPUS:85106643002
SN - 2374-7943
VL - 7
SP - 724
EP - 738
JO - ACS Central Science
JF - ACS Central Science
IS - 5
ER -